In addition, pembrolizumab treatment resulted in fewer adverse events (AEs) among patients with metastatic NSCLC without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or greater (12). This evidence concerns the gene CD274 and neoplasm.